Atea Pharmaceuticals (NASDAQ: AVIR) is a clinical-stage biopharmaceutical company focused on developing antiviral medicines. It has generated no product revenue since inception and funds operations entirely through capital markets activity. As of the 10-K filed March 5, 2026, the company's primary clinical program is a combination regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV), with ruzasvir licensed from Merck under a December 2021 agreement. A second candidate, AT-587, targets hepatitis E virus (HEV) and is in preclinical and early clinical development. The company holds cash, cash equivalents, and marketable securities it believes will fund planned operations through 2027. Atea is headquartered in Boston, Massachusetts and operates under an office sublease expiring December 31, 2026. No products have received regulatory approval, and the company does not anticipate product sales revenue in the near term.

Revenue model

No product revenue has been generated since inception (as stated in the 10-K filed 2026-03-05). Operations are funded through equity issuances. Minor cash inflows have come from the Employee Stock Purchase Plan, which provided $0.3 million in net financing activity for the year ended December 31, 2024.

Products and services

Bemnifosbuvir (HCV nucleotide polymerase inhibitor, clinical stage), ruzasvir (NS5A inhibitor licensed from Merck, clinical stage, HCV combination partner), AT-587 (HEV antiviral candidate, preclinical and early clinical stage). No products are approved for commercial sale as of the filing date.

Customers and end markets

No commercial customers as of the 10-K filed 2026-03-05. Target end markets upon potential approval would be patients with hepatitis C virus and hepatitis E virus infections.

Value-chain role

Drug developer without commercial products. Relies on contract research organizations (CROs) for preclinical and clinical studies and contract manufacturing organizations (CMOs) for manufacture and supply of product candidates. Holds a license from Merck (MSD International GmbH) for ruzasvir covering development, manufacture, and commercialization rights.

Geographic exposure

Headquartered in Boston, Massachusetts. Subject to EU GDPR and UK GDPR/Data Protection Act 2018 in connection with clinical operations, indicating some international trial activity. No commercial geographic revenue mix disclosed.

Source: SEC 10-K, filed 2026-03-05

Industry: Pharmaceutical Preparations Peers: ANI Pharmaceuticals Inc Tvardi Therapeutics Inc Collegium Pharmaceutical Inc Edgewise Therapeutics Inc Esperion Therapeutics Inc Evolus Inc Johnson & Johnson Nuvation Bio Inc Phibro Animal Health Corp Tricida, Inc.